We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Oncology Biomarker Database Includes Cancer Companion Diagnostic Pathway

By LabMedica International staff writers
Posted on 29 Dec 2011
A comprehensive cancer biomarker database has been launched that can help in finding new diagnostic, prognostic, and companion diagnostic biomarkers.

The database includes cancer companion-diagnostics biomarker pathway maps. More...
It contains more than 8,500 discovery phase, preclinical, or clinical cancer biomarkers that were identified or validated using patient derived samples.

Sciclips (Madison, MI, USA) launched the database, which covers a wide variety of biomarkers such as blood cancer biomarkers (peripheral blood, plasma, serum etc), tumor biomarkers, urinary cancer biomarkers, fecal cancer biomarkers, saliva cancer biomarkers, breath cancer biomarkers, etc.

More than 100 types of cancer are included in the cancer biomarker database. For each cancer type, the biomarkers are classified into diagnostic biomarkers; for the diagnostics application, disease predictive/risk assessment biomarkers; for predicting the risk or genetic susceptibility in developing cancer; drug efficacy/response biomarkers; biomarkers for studying the efficacy of anticancer drug treatments, including predictive biomarkers and prognostic biomarkers; and for determining the clinical outcome in cancer patients.

The types of cancer biomarkers include protein biomarkers, miRNA biomarkers, single-nucleotide polymorphism (SNP) biomarkers, gene expression biomarkers, epigenetic biomarkers, and metabolomic biomarkers.

With the growing trend of personalized healthcare concept and advance in biomarker research, there is a need for development of innovative personalized cancer drugs with companion biomarker assays to identify the most appropriate cancer patient, tumor type, and disease state.

Patient/sample details, experimental results, observations, biological and molecular functional analysis, biological process analysis, protein-protein interaction networks of each biomarker are listed in the database.

The pathway maps will help to identify new anticancer drug predictive and response biomarkers, for the discovery of new drug targets with improved efficacy or targeted therapy to overcome side effects, patient stratification, developing personalized strategies for monitoring cancer progression, treatment, diagnosis, and prognosis.

Related Links:

Sciclips




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.